Back

Exploratory mediation analysis of the effect of semaglutide on cardiovascular outcomes in people with overweight or obesity in the SELECT randomised trial

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Obesity and pre-diabetes: where do we stand today on prevention and treatment? Secondary Prevention ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Steven Kahn

VA Puget Sound Health Care System and University of Washington, Seattle (United States of America)

4 More presentations in this session

Presentation thumbnail
State-of-the-art lecture on obesity and pre-diabetes: where do we stand today on prevention and treatment?
Professor E. Prescott (Copenhagen, DK)
Slides Video
Presentation thumbnail
Are metabolically healthy obese individuals really a benign cardiovascular group? An analysis of 162,590 participants with measures of arterial stiffness in UK BIOBANK
Doctor R. Ananda (Melbourne, AU)
Abstract Slides Video
Presentation thumbnail
Association between normal range UACR and insulin resistance and prediabetes among US adults:
Miss S. Wu (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Cardiovascular prevention with GLP1 agonists in high or very-high cardiovascular risk irrespective of diabetes.
Doctor N. del-Cuerpo-Salinas (Sant Joan d'Alacant, ES)
Abstract Slides Video

Access the full session

Session thumbnail
Obesity and pre-diabetes: where do we stand today on prevention and treatment?
Video

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
How has the concept of incretin mimetics evolved since SELECT?
thumbnail
Congress Presentation
Semaglutide is associated with lower risk of cardiovascular events compared with tirzepatide in patients with overweight or obesity and ASCVD and without diabetes in routine clinical practice
thumbnail
Congress Presentation
Getting to the heart of the matter: GLP1 receptor agonists and cardiovascular disease

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources